Identification of the novel KI polyomavirus in the respiratory tract of an Italian patient

2008 ◽  
Vol 80 (11) ◽  
pp. 2012-2014 ◽  
Author(s):  
Muhammed Babakir-Mina ◽  
Massimo Ciccozzi ◽  
Salvatore Dimonte ◽  
Francesca Farchi ◽  
Catia Valdarchi ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
The Novel ◽  
Italian Patient ◽  
Ki Polyomavirus

Identification of the novel HLA‐DRB1 *03:01:32. New allele in an Italian patient

HLA ◽  
2021 ◽  
Author(s):  
T. Galluccio ◽  
M. C. Artesiani ◽  
M. Troiano ◽  
G. Testa ◽  
M. Andreani
Keyword(s):  
The Novel ◽  
Italian Patient

scholarly journals Identification of a Third Human Polyomavirus

2007 ◽  
Vol 81 (8) ◽  
pp. 4130-4136 ◽  
Author(s):  
Tobias Allander ◽  
Kalle Andreasson ◽  
Shawon Gupta ◽  
Annelie Bjerkner ◽  
Gordana Bogdanovic ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Large Scale ◽  
Severe Disease ◽  
Amino Acid Identity ◽  
Human Polyomavirus ◽  
Clinical Samples ◽  
Human Pathogens ◽  
Human Respiratory Tract ◽  
Ki Polyomavirus ◽  
Virus Screening

ABSTRACT We have previously reported on a system for large-scale molecular virus screening of clinical samples. As part of an effort to systematically search for unrecognized human pathogens, the technology was applied for virus screening of human respiratory tract samples. This resulted in the identification of a previously unknown polyomavirus provisionally named KI polyomavirus. The virus is phylogenetically related to other primate polyomaviruses in the early region of the genome but has very little homology (<30% amino acid identity) to known polyomaviruses in the late region. The virus was found by PCR in 6 (1%) of 637 nasopharyngeal aspirates and in 1 (0.5%) of 192 fecal samples but was not detected in sets of urine and blood samples. Since polyomaviruses have oncogenic potential and may produce severe disease in immunosuppressed individuals, continued searching for the virus in different medical contexts is important. This finding further illustrates how unbiased screening of respiratory tract samples can be used for the discovery of diverse virus types.

scholarly journals Being aware of the neurological manifestations of COVID-19 infection

2021 ◽  
Vol 40 (3) ◽  
pp. 187-189
Author(s):  
Basak Atalay
Keyword(s):  
Respiratory Tract ◽  
Sore Throat ◽  
Strong Evidence ◽  
Initial Presentation ◽  
The Novel ◽  
Neurologic Manifestations ◽  
Neurological Manifestations ◽  
Impaired Consciousness ◽  
Atypical Symptoms ◽  
Novel Coronavirus

The novel coronavirus disease- 2019 (COVID-19) is first reported from China, and unfortunately, no longer restricted, and spreads in all geographies.(1) The main symptoms of COVID-19 infection are respiratory tract related. Infected patients usually have symptoms such as fever, sore throat, and fatigue, and they may have atypical symptoms like headache, seizure, anosmia, stroke, and even impaired consciousness. Strong evidence of an association between COVID-19 infection and neurological manifestations has been reported. Besides, the neurologic manifestations may be the initial presentation of COVID-19 infection.

scholarly journals Status of chloroquine and hydroxychloroquine in COVID-19 infection

2020 ◽  
Vol 9 (8) ◽  
pp. 1301
Author(s):  
Savita Ramesh Shahani ◽  
Lokesh R. Shahani
Keyword(s):  
Clinical Trials ◽  
Tract Infection ◽  
Respiratory Tract ◽  
Rna Virus ◽  
International Committee ◽  
The Novel ◽  
Human Respiratory Tract ◽  
Novel Virus ◽  
Dose Dependent

COVID-19 causing virus is a single stranded RNA virus which has spread across the globe causing human respiratory tract infection. The novel virus which started from Wuhan was named as Wuhan coronavirus or 2019 novel corona virus (2019-nCov) by the Chinese researchers. The international committee on taxonomy of viruses named the virus as SARS-CoV-2 and the disease as COVID-19. There is preliminary in vitro evidence of the ability of CQ and HCQ to inhibit SARS-CoV-2 activity. Various small group clinical studies conducted in china indicated efficacy of chloroquine and hydroxychloroquine in Covid-19 cases but results were inconclusive. Based on these studies national agencies in various countries issued guidelines mentioning that chloroquine and Hydroxychloroquine are only to be used in clinical trials or emergency use programs. However, USFDA does not recommend use of both these drugs for treatment of COVID-19 cases. Chloroquine and hydroxychloroquine are known to produce dose dependent toxicity including fatal arrhythmias therefore its possible benefit has to be assessed against its risk. Large number of international and national studies are ongoing to assess exact status of chloroquine and hydroxychloroquine for treatment and prophylaxis of COVID-19 infection. Based on these results ICMR recommend to use hydroxychloroquine for prophylaxis of COVID-19 in India and hydroxychloroquine has been is included  in schedule H1 hence they can be sold by pharmaceutical chemists only strictly with a valid prescription and require record to be maintained but chloroquine is still under schedule H which require to be sold with prescription. 

scholarly journals Population Bottlenecks and Intra-host Evolution During Human-to-Human Transmission of SARS-CoV-2

2021 ◽  
Vol 8 ◽  
Author(s):  
Daxi Wang ◽  
Yanqun Wang ◽  
Wanying Sun ◽  
Lu Zhang ◽  
Jingkai Ji ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Stochastic Dynamics ◽  
The Novel ◽  
Population Bottlenecks ◽  
Human Respiratory Tract ◽  
Human Coronavirus ◽  
Active Viral Replication ◽  
Host Evolution ◽  
Replication Activity

The emergence of the novel human coronavirus, SARS-CoV-2, causes a global COVID-19 (coronavirus disease 2019) pandemic. Here, we have characterized and compared viral populations of SARS-CoV-2 among COVID-19 patients within and across households. Our work showed an active viral replication activity in the human respiratory tract and the co-existence of genetically distinct viruses within the same host. The inter-host comparison among viral populations further revealed a narrow transmission bottleneck between patients from the same households, suggesting a dominated role of stochastic dynamics in both inter-host and intra-host evolutions.

KI Polyomavirus Detected in Respiratory Tract Specimens From Patients in St. Louis, Missouri

2009 ◽  
pp. 1 ◽  
Author(s):  
David J. Hormozdi ◽  
Max Q. Arens ◽  
Binh-Minh Le ◽  
Richard S. Buller ◽  
Eugene Agapov ◽  
...  
Keyword(s):  
Respiratory Tract ◽  
Ki Polyomavirus

scholarly journals Viral Shedding Time of SARS-CoV-2 and the Factors Involved: A Retrospective Observational Study

2021 ◽  
Author(s):  
Guixian Wu ◽  
Ling Lin ◽  
Susu He ◽  
Qian Chen ◽  
Xiaomai Wu ◽  
...  
Keyword(s):  
Observational Study ◽  
Respiratory Tract ◽  
Digestive Tract ◽  
Severe Disease ◽  
Advanced Age ◽  
Retrospective Observational Study ◽  
The Novel ◽  
Clearance Time ◽  
Viral Shedding ◽  
Novel Coronavirus

Abstract Background: In December 2019, the discovery of the novel coronavirus was first reported in Wuhan, China, which subsequently and rapidly spread throughout the country and worldwide, resulting in a pandemic.After a year of intense research, our knowledge of the new coronaviruses has gradually improved; however, knowledge regarding the time of their complete clearance from the body and the factors influencing clearance are currently inadequate. Results: We conducted a retrospective observational study comprising 135 patients above the age of 18 years with a confirmed diagnosis of COVID-19 pneumonia, who were admitted to the Public Health Center of Taizhou Hospital of Zhejiang Province, Zhejiang University from January 23, 2020, to March 11, 2020. The findings regarding the duration of the infection from the time of onset to the time of being asymptomatic (whichever was observed first) indicated that novel coronaviruses were cleared from the respiratory tract in a maximum of 84 days and a minimum of 1 day with a median clearance time (quartile) of 20 (13, 30) days. Moreover, viruses were cleared from the digestive tract in a maximum of 72 days and a minimum of 5 days with a median clearance time (quartile) of 25 (20.75, 31) days. The viral shedding time of SARS in the digestive tract was found to be longer than that in the respiratory tract (p = 0.03). Severe disease (P < 0.001), advanced age (P < 0.001), lymphopenia (P = 0.01) and elevated CRP (P = 0.036) were significantly associated with longer clearance time in the respiratory tract. Gender (P = 0.754), novel coronavirus antibodies (P = 0.75), and antibiotic use (P = 0.093) were not associated with the time span required for the novel coronavirus to be cleared from the respiratory tract. Conclusions: Independent risk factors for the longer clearance time of novel coronaviruses in the digestive tract versus that in the respiratory tract were compared. Severe disease, advanced age, lymphopenia, and elevated CRP were determined to be factors prolonging the clearance of novel coronaviruses.

Sign in / Sign up

Export Citation Format

Share Document